News

DelveInsight Business Research, LLP: Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer ...
The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...
Pulmonology Advisor49m
FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations
The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
Targeted Oncology1h
Future Directions and Unmet Needs in CLL/SLL Treatment
Panelist discusses how recent ASCO updates, particularly the SEQUOIA study results, highlight the long-term efficacy of zanubrutinib in high-risk patients and represent the most significant advances ...
Physician's Weekly17h
Q&A: Validated AI Model Could Guide Real-World NSCLC Decisions
Drs. Fatemeh Ardeshir-Larijani and Mohamed Abazeed discuss a validated AI model that can predict how patients with advanced ...
Most patients with advanced melanoma remain disease-free 4 years after pre-surgical immunotherapy, study finds
Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...
Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation of T cells. The growing prevalence of autoimmune ...